Quick Answer
PLUS THERAPEUTICS, INC. reported Cash and Equivalents of $4.26 million for fiscal year 2025.
PLUS THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.26M | +5500.0% |
| 2024 | $76.0K | -99.1% |
| 2023 | $8.55M | -52.8% |
| 2022 | $18.12M | -1.5% |
| 2021 | $18.40M | +120.5% |
| 2020 | $8.35M | -52.4% |
| 2019 | $17.55M | +233.6% |
| 2018 | $5.26M | -44.9% |
| 2017 | $9.55M | -24.2% |
| 2016 | $12.60M | -12.1% |
| 2015 | $14.34M | -1.9% |
| 2014 | $14.62M | -5.7% |
| 2013 | $15.51M | -39.7% |
| 2012 | $25.72M | -30.3% |
| 2011 | $36.92M | -29.9% |
| 2010 | $52.67M | +309.7% |
| 2009 | $12.85M | +1.9% |
| 2008 | $12.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.29M | +986.6% | +495.1% |
| June 30, 2025 | $2.23M | -54.5% | -77.4% |
| March 31, 2025 | $9.87M | +240.1% | +12882.9% |
| December 31, 2024 | $76.0K | -99.1% | -93.8% |
| September 30, 2024 | $1.22M | -88.9% | -75.1% |
| June 30, 2024 | $4.91M | -54.9% | +69.3% |
| March 31, 2024 | $2.90M | -77.2% | -66.1% |
| December 31, 2023 | $8.55M | -52.8% | -22.3% |
- PLUS THERAPEUTICS, INC. showed an increase of +5500.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, PLUS THERAPEUTICS, INC.’s cash and equivalents has declined by 66.3% (from $12.61 million to $4.26 million).
- The most recent figure is from PLUS THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: